Status: In preparation. Protocol OSMF-VS4P-001. Registration and ethics review pending. Not currently enrolling.

Long COVID: Competing & Complementary Hypotheses

Long COVID is increasingly viewed not as a single disease but as a syndrome that may arise through multiple biological pathways. Different patients may have different dominant mechanisms, and several may coexist in the same person. Twelve leading hypotheses currently under active investigation.

How to use this page: Each card below is a working hypothesis, not a settled fact – the badge in the top right reflects how broadly supported the mechanism currently is (Established → Supported → Emerging → Contested → Mechanistic-only). Where the site has a dedicated data page for a hypothesis, a link appears at the bottom of the card. Most patients likely have more than one mechanism active at once – see the Integrated Multi-Hit Model and Endotypes page for how these combine.

1 Viral Persistence Supported

SARS-CoV-2 or viral components remain in the body long after the initial infection.
Possible mechanisms
  • Persistent viral replication in tissue reservoirs
  • Persistence of viral RNA without active replication
  • Long-lived viral proteins (especially spike or nucleocapsid)
  • Intermittent viral reactivation from reservoirs
Potential reservoir sites
  • Gastrointestinal tract, lymphoid tissue, brain, bone marrow, cardiovascular tissue, adipose tissue
Evidence
  • Viral RNA detected months after infection
  • Viral proteins identified in blood and tissues
  • Improvement in some patients on antivirals – though trial evidence remains mixed
If dominant, treatments might include
  • Antivirals, combination antiviral therapy, therapeutic vaccines, immune-enhancing therapies

2 Immune Dysregulation Supported

Rather than a virus actively causing damage, the immune system may remain "stuck" in an activated or dysfunctional state.
Examples
  • Persistent activation of T cells; exhausted T cells
  • Altered B-cell populations
  • Chronic cytokine production
  • Reduced interferon responses
If dominant, treatments might include
  • Immunomodulators, low-dose immune therapies, cytokine-targeted treatments
See cytokine & immunological data →

3 Autoimmunity Supported

COVID-19 can trigger autoimmune responses against the patient's own tissues.
Identified autoantibodies
  • Against GPCRs (G-protein coupled receptors)
  • Antinuclear antibodies
  • Antibodies affecting vascular function
  • Antibodies targeting nervous system components
Possible mechanisms
  • Molecular mimicry, bystander activation, epitope spreading
May contribute to
  • Dysautonomia, neurological dysfunction, fatigue, joint pain
If dominant, treatments might include
  • B-cell depletion, IVIG, immunosuppressive drugs, plasmapheresis (under investigation)

4 Microclotting & Endothelial Dysfunction Supported

Persistent abnormalities in blood clotting may reduce oxygen delivery despite normal large-vessel circulation.
Reported findings
  • Fibrin amyloid microclots
  • Activated platelets
  • Endothelial injury
  • Impaired microcirculation
Potential symptoms
  • Exercise intolerance, brain fog, muscle fatigue, chest discomfort
Under study (not yet standard of care)
  • Anticoagulants, antiplatelet therapy, fibrinolytic strategies
See coagulopathy data →

5 Mitochondrial Dysfunction Supported

Impaired cellular energy production, resembling the metabolic abnormalities seen in ME/CFS.
Findings
  • Reduced ATP production
  • Altered fatty acid metabolism
  • Oxidative stress
  • Reduced aerobic capacity
If dominant, treatments might include
  • Metabolic support, exercise pacing, mitochondrial-targeted supplements, experimental metabolic therapies
See mitochondria diagram & metabolite data →

6 Autonomic Nervous System Dysfunction Supported

Dysautonomia develops in many patients, disrupting involuntary body regulation.
Common manifestations
  • POTS (postural orthostatic tachycardia syndrome)
  • Orthostatic intolerance
  • Blood pressure instability
  • Abnormal heart rate regulation
  • Gastrointestinal dysfunction
Possible causes
  • Autoimmunity, small fiber neuropathy, viral injury, persistent inflammation
See norepinephrine & catecholamine data →

7 Small Fiber Neuropathy Emerging

Damage to small sensory and autonomic nerve fibers has been documented in a subset of patients.
Symptoms
  • Burning pain, tingling, temperature sensitivity
  • Autonomic dysfunction, gastrointestinal symptoms
Diagnosis
  • Often requires skin biopsy or specialized autonomic testing

8 Reactivation of Latent Viruses Emerging

Immune disruption from COVID-19 may allow dormant viruses to reactivate or become more immunologically significant.
Viruses under investigation
  • Epstein–Barr virus (EBV)
  • Human herpesvirus 6 (HHV-6)
  • Cytomegalovirus (CMV)

9 Gut Dysbiosis Emerging

COVID-19 can substantially alter the gut microbiome, with downstream systemic effects.
Observed changes
  • Reduced microbial diversity
  • Loss of beneficial bacteria
  • Increased inflammatory organisms
  • Increased intestinal permeability ("leaky gut")
Potential downstream effects
  • Immune activation, systemic inflammation, altered metabolism, neuroinflammation
See gut-metabolite data →

10 Neuroinflammation Emerging

Brain imaging and biomarker studies suggest persistent inflammation affecting the central nervous system.
Possible mechanisms
  • Activated microglia, astrocyte activation
  • Blood-brain barrier dysfunction
  • Persistent inflammatory signaling
May contribute to
  • Brain fog, memory impairment, cognitive slowing, sleep disturbances
See glutamate/GABA & neuro data →

11 Persistent Tissue Damage Emerging

Some symptoms may result from structural injury sustained during acute infection, persisting after the infection itself has resolved.
Examples
  • Lung fibrosis
  • Cardiac injury
  • Kidney damage
  • Olfactory nerve injury

Framework12. Integrated Multi-Hit Model

Many researchers now favor a model in which several mechanisms interact rather than a single cause explaining all cases. This framework could explain why patients with similar initial infections experience very different long-term outcomes, and why a single therapy may not benefit everyone.

1. Acute SARS-CoV-2 infection
→
2. Viral persistence in tissues
→
3. Chronic immune activation
→
4. Autoantibody development
→
5. Endothelial & microvascular injury
→
6. Mitochondrial dysfunction
→
7. Dysautonomia & impaired energy production
→
8. Persistent symptoms

See the Endotypes page for how these mechanisms cluster into distinct patient subgroups (persistence-dominant, autoimmune-dominant, metabolic/PEM-dominant, vascular-dominant).

Which hypotheses currently have the strongest support?

While the field is still evolving, the most actively investigated and broadly supported mechanisms include:

Supported Viral persistence – viral RNA, proteins, or in some cases replication-competent virus persisting in tissue reservoirs
Supported Immune dysregulation – persistent abnormalities in innate and adaptive immune responses
Supported Autoimmunity – autoantibody development and immune-mediated dysfunction
Supported Endothelial dysfunction & microvascular abnormalities – including clotting and vascular injury
Supported Autonomic nervous system dysfunction – especially POTS and related syndromes
Supported Mitochondrial & metabolic dysfunction – impaired cellular energy production

These mechanisms are not mutually exclusive. The current consensus in the field is moving toward viewing Long COVID as a heterogeneous condition with multiple biological subtypes, rather than a single disease driven by one underlying process.